#drug development

Bain Capital has officially launched Beeline Medicines with five assets from Bristol Myers Squibb, creating a new biotech centered on shelved immunology drugs.

A randomized phase 2 trial in Nature Medicine found that adding elraglusib to gemcitabine plus nab-paclitaxel improved median overall survival and one-year survival in previously untreated metastatic pancreatic ductal ad

Roche is expanding work with longtime partner C4 Therapeutics in a deal worth $20 million upfront, underscoring rising interest in degrader-antibody conjugates as a new twist on an already hot cancer-drug category.

A long-stagnant field is moving again as tuberculosis drug and vaccine development reaches its broadest pipeline on record, raising the prospect of shorter treatments and the first new vaccine class in a century.

Tanabe Pharma says it has posted positive Phase 3 data for an oral drug targeting two rare disorders associated with pain on light exposure, marking a major clinical milestone after its Bain Capital acquisition.

Biogen says its anti-BDCA2 antibody litifilimab improved skin lesions after 24 weeks in a Phase 2 lupus study, giving the company a clinical win for a program it hopes will anchor its immunology pipeline.

Otsuka is acquiring private biotech Transcend Therapeutics in a deal worth roughly $1.2 billion, extending big pharma’s interest in neuropsychiatric medicines modeled on the therapeutic promise associated with psychedel

New research says early-stage drug development has nearly doubled worldwide over the past decade and moved from a U.S.-dominated model to a dual hub centered on the United States and China.

A newly identified ion channel called TRPV4 acts as the brain's internal braking system for scratching, sending a 'that's enough' signal through sensory neurons. The finding could reshape how researchers develop treatments for chronic itch conditions such as eczema and psoriasis.